The Signos Glucose Monitoring System is a mobile device application that receives data from an OTC integrated continuous ...

In October 2024, Imuldosa received approval from the Food and Drug Administration based on data from the phase 3 Opportuniti ...

HealthDay News — For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target (<120 mm Hg) seems cost-effective ...

OTC access linked to 31.8 percentage point increase in individuals moving from no contraceptive method to an effective method.

Exposure to vaginal estradiol not linked to increased rate of recurrent ischemic stroke when adjusted for comorbidity, medications, income, education ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

The approval was supported by data from 3 double-blind, placebo-controlled trials that included a total of 1474 patients who met the 2016 ACR criteria for diagnosis of fibromyalgia.

Findings showed inclacumab did not statistically significantly reduce the rate of VOCs compared with placebo after 48 weeks. Topline data were announced from a phase 3 study evaluating inclacumab, an ...

AA clinical program includes 2 replicate pivotal studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

Significant decrease seen in serum levels of vascular endothelial growth factor and interleukin-1 receptor antagonist at 12 months.

"The very experts trained to understand, interrupt and prevent this kind of violence were among those whose jobs were eliminated." ...